IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 136,409 shares of the medical research company’s stock after selling 3,999 shares during the period. IQVIA makes up approximately 2.2% of Washington Trust Advisors Inc.’s holdings, making the stock its 13th biggest position. Washington Trust Advisors Inc.’s holdings in IQVIA were worth $26,806,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC lifted its position in shares of IQVIA by 35.2% in the third quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock worth $96,000 after buying an additional 106 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in IQVIA during the third quarter valued at about $218,000. Robeco Institutional Asset Management B.V. grew its stake in shares of IQVIA by 0.6% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 118,394 shares of the medical research company’s stock valued at $28,056,000 after purchasing an additional 674 shares during the period. Asset Management One Co. Ltd. grew its stake in shares of IQVIA by 1.3% in the 3rd quarter. Asset Management One Co. Ltd. now owns 71,077 shares of the medical research company’s stock valued at $16,843,000 after purchasing an additional 888 shares during the period. Finally, QRG Capital Management Inc. grew its stake in shares of IQVIA by 2.1% in the 3rd quarter. QRG Capital Management Inc. now owns 6,190 shares of the medical research company’s stock valued at $1,467,000 after purchasing an additional 130 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Tuesday. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Up 1.3 %

Shares of IQV stock opened at $186.04 on Thursday. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a 50-day simple moving average of $198.24 and a two-hundred day simple moving average of $213.66. The company has a market capitalization of $32.80 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.